NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $1.34 +0.01 (+0.75%) As of 12:21 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Telomir Pharmaceuticals Stock (NASDAQ:TELO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TELO alerts:Sign Up Key Stats Today's Range$1.28▼$1.3650-Day Range$1.14▼$1.4852-Week Range$1.05▼$3.10Volume56,987 shsAverage Volume144,873 shsMarket Capitalization$46.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited. The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation. Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.AI Generated. May Contain Errors. Read More Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TELO Stock News HeadlinesTelomir Pharmaceuticals Receives FDA IND Clearance for Telomir-ZnApril 30, 2026 | tipranks.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher - Here's What HappenedApril 25, 2026 | americanbankingnews.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.May 6 at 1:00 AM | Weiss Ratings (Ad)Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)April 24, 2026 | usatoday.comTelomir Pharmaceuticals Inc.April 2, 2026 | barrons.comTelomir seeks FDA approval for Telomir-1 to treat breast cancerApril 2, 2026 | msn.comTelomir Pharmaceuticals Regains Nasdaq Listing Rule ComplianceMarch 31, 2026 | tipranks.comTelomir Shareholders Approve Equity Plan and Bylaw ChangesMarch 27, 2026 | tipranks.comSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $1.33 at the start of the year. Since then, TELO stock has increased by 0.8% and is now trading at $1.34. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced its earnings results on Tuesday, March, 17th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO. How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/17/2026Today5/06/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TELO's financial health is in the Green zone, according to TradeSmith. TELO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(737)-289-0835FaxN/AEmployees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-315.26% Return on Assets-259.29% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book7.88Miscellaneous Outstanding Shares34,380,000Free FloatN/AMarket Cap$46.07 million OptionableN/A Beta-0.21 7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free Report This page (NASDAQ:TELO) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts